Liège, Belgium, April 26, 2022 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, announces today that it has signed a partnership agreement with MedinCell for the development of two long-acting injectable products within its Mithra CDMO located in Liège.
The Mithra CDMO offers a wide range of services ranging from early drug development to clinical batches, through the commercial production of complex polymer-based products (vaginal rings, implants) and complex liquid injectables and biologics, both in vials, pre-filled syringes or cartridges.
Disclaimer
Mithra Pharmaceuticals SA published this content on April 26, 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on April 26, 2022 05:39:02 UTC.